This is a preview of subscription content, log in via an institution to check access.
Acknowledgments
I thank all presenters at the Summit for their contribution and to those who have contributed to the fruitful discussions. Elisabeth Peen is also thanked for comments on this report. The Summit was organized by Ian Ahnfelt-Rønne, Lisa Marshall, Kouji Matsushima, Elisabeth Peen and John Hamilton. We thank the following sponsors: Abbott, Abide Therapeutics, Biogen Idec, Celgene, Chugai Pharmaceutical Co., Ltd, GlaxoSmithKline, Janssen, Kyowa-Hakko-Kirin Co. Ltd, MedImmune, Novo Nordisk, Pfizer Inc., Roche Group and Regeneron Pharmaceuticals. A full report of the Summit and cited literature can be viewed on the IAIS website http://inflammationsocieties.org/.
Conflict of interest
The author declares no competing financial interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: Michael J. Parnham.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hamilton, J.A. Therapeutic potential of targeting inflammation. Inflamm. Res. 62, 653–657 (2013). https://doi.org/10.1007/s00011-013-0614-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-013-0614-3